solid bio (SLB) to Dose First Patient in Impact Duchenne Phase 3 Trial in Q1 2026

Solid Biosciences (SLB) announced it will dose the first patient in its Phase 3 trial for the Impact Duchenne treatment in the first quarter of 2026. The pivotal trial, which evaluates the safety and efficacy of the therapy in boys with Duchenne muscular dystrophy, is designed to enroll up to 600 patients across the United States and Europe. The company expects to report top-line results in the second half of 2026, pending enrollment completion. The trial is a key step toward potential regulatory approval, with the goal of demonstrating significant improvement in ambulatory function.